Sentry Technology Corp. (SKVY)

Revance Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009
Period Ending	Mar 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009
Net Income	-	-	-	-	-1.53	-1.85
Depreciation & Amortization	-	-	-	-	0.15	0.13
Other Amortization	-	-	-	-	0.77	0.51
Stock-Based Compensation	-	-	-	-	0.03	0.02
Other Operating Activities	-	-	-	-	0.2	0.13
Change in Accounts Receivable	-	-	-	-	-0.26	0.1
Change in Inventory	-	-	-	-	0.11	0.74
Change in Accounts Payable	-	-	-	-	0.08	0.04
Change in Unearned Revenue	-	-	-	-	0.01	0.01
Change in Other Net Operating Assets	-	-	-	-	-0.06	-0.24
Operating Cash Flow	-	-	-	-	-0.52	-0.36
Capital Expenditures	-	-	-	-	-0.05	-0.06
Investment in Securities	-	-	-	-	-	0.11
Other Investing Activities	-	-	-	-	-0.05	-0.02
Investing Cash Flow	-	-	-	-	-0.09	0.02
Short-Term Debt Issued	-	-	-	-	0.07	0.01
Long-Term Debt Issued	-	-	-	-	0.45	-
Total Debt Issued	-	-	-	-	0.52	0.01
Net Debt Issued (Repaid)	-	-	-	-	0.52	0.01
Financing Cash Flow	-	-	-	-	0.52	0.01
Foreign Exchange Rate Adjustments	-	-	-	-	0.02	-0
Net Cash Flow	-	-	-	-	-0.07	-0.33
Free Cash Flow	-	-	-	-	-0.57	-0.42
Free Cash Flow Margin	-	-	-	-	-5.74%	-4.32%
Free Cash Flow Per Share	-	-	-	-	-0.01	-0.00
Cash Interest Paid	-	-	-	-	0.38	0.34
Cash Income Tax Paid	-	-	-	-	0	0.08
Levered Free Cash Flow	-	-	-	-	-0.45	-0.01
Unlevered Free Cash Flow	-	-	-	-	0.4	0.62
Change in Net Working Capital	-0.6	-0.5	-0.83	-4.95	0.43	-0.41

Source: S&P Global Market Intelligence. Standard template. Financial Sources.